Bayer Menopause Drug Lands FDA Approval, Bringing Competition to an Astellas Product

A Bayer drug that hits two central nervous system targets to treat moderate-to-severe menopause symptoms has FDA approval, introducing a new non-hormonal therapeutic option that may have an advantage over an Astellas Pharma product that has a two-year head start in this market. The Bayer drug, elinzanetant, is a small molecule formulated as a soft…

Read More

Merck’s Injectable Version of Blockbuster Cancer Drug Keytruda Wins FDA Approval

A subcutaneously injected version of Merck cancer immunotherapy Keytruda is now FDA approved, a regulatory decision that gives patients a less burdensome dosing option and provides the pharmaceutical giant a way to retain some market share as the original intravenously infused formulation — its top-selling product — faces patent expirations. The approval announced Friday covers…

Read More